PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

Monday August 31, 2009

PennyOmega.com Stock Report!

**************************************************************

AZN, AstraZeneca plc

A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says.

AZN is ready to launch a challenge to the world’s second-best selling drug.

Tests of AZN’s new blood-thinning drug, designed to treat heart disease, show it performing 16 % better than market leader Plavix, according to research published in the New England Journal of Medicine.

Plavix is a lucrative source of revenue for co-developers Bristol-Myers Squibb (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY)

HUN, Huntsman Corporation

HUN operates as a global manufacturer of differentiated organic chemical products and of inorganic chemical products.

HUN entered a “stalking horse” agreement to buy certain assets of bankrupt rival Tronox Inc (TRXAQ.PK) for $415 million.

VAR, Varian Medical Systems Inc.

VAR is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy.

VAR is introducing the world’s first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities for international cancer clinics.

VAR’s ’s UNIQUE(TM) radiotherapy system is expected to make advanced care more affordable and more widely available to cancer patients around the world.

“VAR added high-tech image-guidance and arc therapy tools to a low energy platform together with our treatment planning and information management software so that technology for fast, state-of-the-art cancer treatments can be made available to treatment centers at a cost under $2 million” said Dow Wilson, VAR’s President

***********Advertisement***********

********************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations.

(more…)